NO307929B1 - Naftylforbindelser, anvendelse av disse for fremstilling av et farmasøytisk preparat, mellomprodukter, sammensetninger inneholdende disse forbindelser eller mellomprodukter, samt fremgangsmÕte for fremstilling av forbindelsene - Google Patents

Naftylforbindelser, anvendelse av disse for fremstilling av et farmasøytisk preparat, mellomprodukter, sammensetninger inneholdende disse forbindelser eller mellomprodukter, samt fremgangsmÕte for fremstilling av forbindelsene

Info

Publication number
NO307929B1
NO307929B1 NO971278A NO971278A NO307929B1 NO 307929 B1 NO307929 B1 NO 307929B1 NO 971278 A NO971278 A NO 971278A NO 971278 A NO971278 A NO 971278A NO 307929 B1 NO307929 B1 NO 307929B1
Authority
NO
Norway
Prior art keywords
compounds
intermediates
preparation
alkyl
pyrrolidinyl
Prior art date
Application number
NO971278A
Other languages
English (en)
Norwegian (no)
Other versions
NO971278L (no
NO971278D0 (no
Inventor
Henry Uhlman Bryant
George Joseph Cullinan
Jeffrey Alan Dodge
Kennan Joseph Fahey
Charles David Jones
Iii Charles Willis Lugar
Brian Stephen Muehl
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO971278D0 publication Critical patent/NO971278D0/no
Publication of NO971278L publication Critical patent/NO971278L/no
Publication of NO307929B1 publication Critical patent/NO307929B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO971278A 1994-09-20 1997-03-19 Naftylforbindelser, anvendelse av disse for fremstilling av et farmasøytisk preparat, mellomprodukter, sammensetninger inneholdende disse forbindelser eller mellomprodukter, samt fremgangsmÕte for fremstilling av forbindelsene NO307929B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/309,525 US7501441B1 (en) 1994-09-20 1994-09-20 Naphthyl compounds, intermediates, processes, compositions, and methods
PCT/US1995/012346 WO1996009039A1 (fr) 1994-09-20 1995-09-18 Composes de naphtyle et intermediaires, processus, compositions et procedes associes

Publications (3)

Publication Number Publication Date
NO971278D0 NO971278D0 (no) 1997-03-19
NO971278L NO971278L (no) 1997-05-14
NO307929B1 true NO307929B1 (no) 2000-06-19

Family

ID=23198583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971278A NO307929B1 (no) 1994-09-20 1997-03-19 Naftylforbindelser, anvendelse av disse for fremstilling av et farmasøytisk preparat, mellomprodukter, sammensetninger inneholdende disse forbindelser eller mellomprodukter, samt fremgangsmÕte for fremstilling av forbindelsene

Country Status (29)

Country Link
US (6) US7501441B1 (fr)
EP (1) EP0703228B1 (fr)
JP (1) JPH10506392A (fr)
KR (1) KR970705983A (fr)
AT (1) ATE214058T1 (fr)
AU (1) AU697114B2 (fr)
BR (1) BR9508967A (fr)
CA (1) CA2200449A1 (fr)
CO (1) CO4410318A1 (fr)
CZ (1) CZ291207B6 (fr)
DE (1) DE69525699T2 (fr)
DK (1) DK0703228T3 (fr)
ES (1) ES2173154T3 (fr)
HU (1) HUT77919A (fr)
IL (1) IL115335A (fr)
MX (1) MX9702154A (fr)
MY (1) MY132075A (fr)
NO (1) NO307929B1 (fr)
NZ (1) NZ294177A (fr)
PE (1) PE47496A1 (fr)
PL (1) PL319454A1 (fr)
PT (1) PT703228E (fr)
RU (1) RU2165924C2 (fr)
SI (1) SI0703228T1 (fr)
TR (1) TR199501135A2 (fr)
TW (1) TW399036B (fr)
WO (1) WO1996009039A1 (fr)
YU (1) YU61595A (fr)
ZA (1) ZA957857B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6451817B1 (en) * 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
GB2312844A (en) * 1996-05-07 1997-11-12 Lilly Co Eli A naphthyl compound for the treatment of immune-complex diseases
US6599920B2 (en) * 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
CA2213814A1 (fr) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Composes naphtaleniques, intermediaires, formulations et methodes
SI0826679T1 (en) * 1996-08-29 2002-04-30 Eli Lilly And Company Naphthyl compounds and compositions
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2214070C (fr) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphtalenes et naphtalenes, intermediaires, formulations et methodes
CA2214931A1 (fr) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorenes et methode d'utilisation
CA2215856A1 (fr) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzofluorenes, intermediaires, compositions et methodes
CA2214929A1 (fr) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphtofluorenes, intermediaires, compositions et methodes
CA2214196A1 (fr) * 1996-09-26 1998-03-26 Eli Lilly And Company Composes de dihydrobenzo[b]indeno[2,1-d]thiophene, intermediaires, procedes, compositions et methodes
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2216592C (fr) * 1996-10-24 2006-07-18 Brian Stephen Muehl Composes a base de benzothiophene, intermediaires, compositions et methodes
CA2215647A1 (fr) * 1996-10-24 1998-04-24 Eli Lilly And Company Composes a base de naphtyle, compositions et methodes
CA2214872C (fr) * 1996-10-24 2002-01-22 Eli Lilly And Company Composes a base de benzothiophene, compositions et methodes
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
IT1298159B1 (it) * 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
WO1998048806A1 (fr) * 1997-04-25 1998-11-05 Eli Lilly And Company Composes d'indene servant de modulateurs serm
JP2001513501A (ja) * 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
CA2306489A1 (fr) 1997-10-03 1999-04-15 Mark Gregory Stocksdale Benzothiophenes
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1395563B1 (fr) 2001-05-22 2006-03-29 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
EP1530470B9 (fr) 2002-07-22 2010-04-07 Eli Lilly And Company Modulateurs selectifs des recepteurs oestrogeniques contenant un groupe phenylsulfonyle
JP2007537991A (ja) * 2003-02-25 2007-12-27 イーライ リリー アンド カンパニー 溶媒和していない結晶性１−（４−（２−ピペリジニルエトキシ）フェノキシ）−２−（４−メタンスルホニルフェニル）−６−ヒドロキシナフタレン塩酸塩
US20060167051A1 (en) * 2003-02-25 2006-07-27 Remick David M Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
BRPI0407690A (pt) 2003-02-25 2006-03-01 Lilly Co Eli composto, e, métodos para tratar endometriose e para tratar leiomioma uterino
ATE515493T1 (de) * 2003-03-31 2011-07-15 Council Scient Ind Res Mercaptophenylnaphthylmethan-derivate und deren herstellung
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
WO2005051298A2 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2005060946A1 (fr) * 2003-12-17 2005-07-07 Pfizer Products Inc. Polytherapie continue avec des agonistes selectifs des recepteurs ep4 de la prostaglandine et un oestrogene pour le traitement de pathologies se manifestant par une faible masse osseuse
EP1709022A1 (fr) * 2004-01-22 2006-10-11 Eli Lilly And Company Modulateurs selectifs du recepteur des oestrogenes
EP1709023B1 (fr) 2004-01-22 2009-11-11 Eli Lilly And Company Modulateurs selectifs du recepteur des oestrogenes
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
JP2007528408A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
US7655700B2 (en) 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
CN102164908B (zh) * 2008-09-29 2013-08-28 伊莱利利公司 用于治疗骨关节炎的选择性雌激素受体调节剂
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
KR20130031339A (ko) 2010-06-16 2013-03-28 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
AU2019223014B2 (en) 2018-02-21 2024-10-17 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3396169A (en) 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
FR90418E (fr) * 1962-09-13 1967-12-08 Ici Ltd Nouveaux dérivés alkéniques
US3862232A (en) 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3320271A (en) 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
DE1300575B (de) 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US3394125A (en) 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
IL45454A (en) * 1973-08-31 1977-06-30 Ciba Geigy Ag 3-methyl-4-(p-phenoxy(or benzyl)-phenoxy)-2-butene derivatives their preparation and pest-population contaol compositions containing them
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2097788B (en) * 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
FR2599031B1 (fr) * 1986-05-23 1988-07-22 Oreal Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US4859695A (en) * 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
US4851554A (en) * 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4122484A1 (de) 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
US6437137B1 (en) 2002-08-20
KR970705983A (ko) 1997-11-03
AU697114B2 (en) 1998-09-24
ATE214058T1 (de) 2002-03-15
EP0703228B1 (fr) 2002-03-06
BR9508967A (pt) 1997-12-30
US7501441B1 (en) 2009-03-10
DK0703228T3 (da) 2002-05-21
US6410564B1 (en) 2002-06-25
MX9702154A (es) 1997-06-28
MY132075A (en) 2007-09-28
PT703228E (pt) 2002-07-31
PE47496A1 (es) 1996-11-12
JPH10506392A (ja) 1998-06-23
US5484796A (en) 1996-01-16
TW399036B (en) 2000-07-21
HUT77919A (hu) 1998-10-28
RU2165924C2 (ru) 2001-04-27
NZ294177A (en) 1998-10-28
CA2200449A1 (fr) 1996-03-28
ZA957857B (en) 1997-03-18
US5484795A (en) 1996-01-16
CZ291207B6 (cs) 2003-01-15
CZ82297A3 (en) 1997-12-17
DE69525699T2 (de) 2002-11-21
DE69525699D1 (de) 2002-04-11
IL115335A0 (en) 1995-12-31
CO4410318A1 (es) 1997-01-09
ES2173154T3 (es) 2002-10-16
WO1996009039A1 (fr) 1996-03-28
NO971278L (no) 1997-05-14
SI0703228T1 (en) 2002-08-31
US5484797A (en) 1996-01-16
NO971278D0 (no) 1997-03-19
EP0703228A1 (fr) 1996-03-27
PL319454A1 (en) 1997-08-04
TR199501135A2 (tr) 1996-06-21
IL115335A (en) 2000-07-26
YU61595A (sh) 1998-09-18
AU3686395A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
NO307929B1 (no) Naftylforbindelser, anvendelse av disse for fremstilling av et farmasøytisk preparat, mellomprodukter, sammensetninger inneholdende disse forbindelser eller mellomprodukter, samt fremgangsmÕte for fremstilling av forbindelsene
YU11496A (sh) Naftilna jedinjenja, njihove farmaceutske formulacije i intermedijari i postupak za njihovo dobijanje
PH23607A (en) Amide derivatives and pharmaceutical composition containing said compounds
DE69628246D1 (de) Naphthyl- und Dihydronaphthylverbindungen als Arzneimittel
ATE253567T1 (de) Benzofuranverbindungen, präparate und verfahren
DE69707611D1 (de) Dihydronaphthalen- und Naphthalenderivate, Zwischenverbindungen, Zusammensetzungen und deren Herstellungsverfahren
DE69726513D1 (de) Benzo[B]thiophenverbindungen,Zwischenprodukte,Verfahren,Zusammensetzungen und Methode
KR970705999A (ko) 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
PT832881E (pt) Compostos de benzofluoreno intermediarios composicoes e metodos
YU34296A (en) Use a compounds for medicament obtaining and pharmaceutical composition thereof
CA2170479A1 (fr) Composes de type benzothiophene; produits intermediaires, compositions et methodes connexes
RS49886B (sr) Benzotiofenska jedinjenja, intermedijari, kompozicije i metode

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MARCH 2003